Epigenomics AG
EPGNY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.95M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.95 Million |
|---|---|
| Enterprise Value | $13.06 Million |
| Annual dividend | $1.27 |
| Earnings per Share | $-0.87 |
| Beta | 1.19 |
| Outstanding Shares | 817,874 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | -62.97% |
| Return on Invested Capital | -61.78% |
Valuation & Multiples
| P/E Ratio | -2.42 |
|---|---|
| PEG | 1.55 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 23.04 |
| Enterprise Value to EBIT | -1.82 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.87 |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Epigenomics AG
3 employees
CEO: Noel Thomas Doheny
Epigenomics AG currently has no significant business activities. Historically, the firm concentrated its efforts on developing liquid biopsy methods for the early identification of cancer. The company was established in 1998 and is based in Heidelberg, Germany.